Skip to main content
. 2005 Feb 25;4:3. doi: 10.1186/1476-069X-4-3

Table 3.

Tetrachloroethylene exposure history of breast cancer subjects, adjusteda odds ratios, and 95% confidence intervals.

Latency period, years Exposed Cases Exposed Controls Adjusted ORs (95 % CI)
0 Non-proxy Subjects 101 88 1.1 (0.8–1.5)
All Subjects 155 136 1.1 (0.8–1.4)
5 Non-proxy Subjects 87 69 1.2 (0.9–1.8)
All Subjects 129 107 1.2 (0.9–1.6)
7 Non-proxy Subjects 71 61 1.1 (0.8–1.6)
All Subjects 111 96 1.1 (0.8–1.5)
9 Non-proxy Subjects 63 57 1.1 (0.7–1.6)
All Subjects 97 85 1.1 (0.8–1.5)
11 Non-proxy Subjects 49 43 1.1 (0.6–1.7)
All Subjects 79 65 1.2 (0.8–1.7)
13 Non-proxy Subjects 43 32 1.3 (0.7–2.1)
All Subjects 61 45 1.3 (0.9–2.0)
15 Non-proxy Subjects 30 21 1.4 (0.7–2.6)
All Subjects 44 31 1.4 (0.9–2.3)
17 Non-proxy Subjects 15 15 1.0 (0.4–2.2)
All Subjects 21 21 1.0 (0.6–2.0)
19 Non-proxy Subjects 6 6 1.1 (0.3–3.5)
All Subjects 9 9 1.1 (0.4–2.9)

a The OR was calculated relative to never-exposed cases (n = 360 for Non-Proxy, n = 517 for ALL) and controls (n = 336 for Non-Proxy, n = 480 for All). Controlled for age at diagnosis or index year, family history of breast cancer, personal history of breast cancer (before current diagnosis or index year), age at first live-birth or still birth, occupational exposure to PCE, and vital status at interview (for All analysis only).